May 16, 2012 - Matteo Zanello, Gian Luigi Adani, Antonio D. ... Bertacco, Martina Gambato, Rafael Ramirez ...... Santoro, Eduardo Sousa Martins Fernandes.
Table of Contents Schedule of Activities ..............................................................................................S3 ILTS Council ............................................................................................................S4 Congress Program Chairs .......................................................................................S5 Acknowledgement of Supporters.............................................................................S6 General Information .................................................................................................S7 Who Should Attend...........................................................................................S7 Goals and Objectives .......................................................................................S7 CME Information ..............................................................................................S7 Scientific Program ............................................................................................S7 Abstracts ..........................................................................................................S7 Poster Sessions ...............................................................................................S8 Registration ......................................................................................................S8 Session Descriptions ........................................................................................S8 Cyber Cafe .....................................................................................................S10 Speaker Slide Check in Room .......................................................................S10 Congress Location .........................................................................................S11 Social Activities...............................................................................................S11 Awards...................................................................................................................S12 Program .................................................................................................................S17 Congress Exhibitors ........................................................................................... S284 Author Index ....................................................................................................... S285 Keyword Index .................................................................................................... S303
1 S1
2 S2
Schedule of Activities All activities will take place at the Hilton San Francisco Union Square Hotel unless otherwise listed. Poster Sessions (Presenters Set-Up and Dismantle) Room: Grand Ballroom B, (GB) Grand Ballroom Level
On-Site Registration, Cyber Café and Speaker Slide Check in Room Hours Room: Yosemite Ballroom, (BR) Ballroom Level Tuesday, May 15, 2012
2:00 pm – 6:00 pm
Wednesday, May 16, 2012
6:30 am – 7:00 pm
Thursday, May 17, 2012
6:30 am – 6:30 pm
Friday, May 18, 2012
6:30 am – 6:30 pm
Saturday, May 19, 2012
6:30 am – 1:00 pm
Poster Session I: Set-Up: Dismantle: Poster Session II: Set-Up: Dismantle: Poster Session III: Set-Up: Dismantle:
Exhibit and Poster Viewing Hours Room: Grand Ballroom B, (GB) Grand Ballroom Level
10:00 am – 6:00 pm
Friday, May 18, 2012
10:00 am – 6:00 pm
Poster Sessions (Presenters in Attendance) Room: Grand Ballroom B, (GB) Grand Ballroom Level Poster Session I Wednesday, May 16, 2012 Poster Session II Thursday, May 17, 2012 Poster Session III Friday, May 18, 2012
Thursday, May 17, 2012 7:00 am – 8:00 am 6:15 pm – 7:00 pm Friday, May 18, 2012 7:00 am – 8:00 am 6:15 pm – 7:00 pm
Posters are to be removed immediately following the end of Poster Viewing at 6:15 pm on Friday, May 18th. Any posters left on the board will be removed and can be picked up at the Congress registration desk before Saturday May 19, 1:00 pm. Any posters not picked up by that time will be discarded.
Wednesday, May 16, 2012 5:30 pm – 7:00 pm Opening Reception, Opening of Exhibits Thursday, May 17, 2012
Wednesday, May 16, 2012 2:00 pm – 5:00 pm 7:00 pm – 7:30 pm
ILTS Business Meeting Room: Continental Ballroom, (BR) Ballroom Level Saturday, May 19, 2012
5:30 pm – 7:00 pm 10:10 am – 10:30 am 4:00 pm – 4:30 pm 10:10 am – 10:30 am 4:00 pm – 4:30 pm
3 S3
9:40 am – 10:00 am
2011 – 2012 ILTS Council Executive Committee President Juan Carlos Garcia-Valdecasas, MD, PhD University of Barcelona Barcelona, Spain
Treasurer Elizabeth A. Pomfret, MD, PhD Lahey Clinic Burlington, MA, USA
President-Elect Richard B. Freeman, Jr., MD Dartmouth School of Medicine Lebanon, NH, USA
Past President Chung Mau Lo, MD The University of Hong Kong Hong Kong, China
Secretary Didier Samuel, MD, PhD Hospital Paul Brousse Villejuif, France
Councilors Patrizia A. Burra, MD, PhD University di Padova Padova, Italy
Sung-Gyu Lee, MD Asan Medical Center Seoul, Korea
Michael R. Charlton, MD Mayo Clinic Rochester, MN, USA
Jan Lerut, MD University Hospital of St. Luc Brussels, Belgium
John R. Klinck, MD, FRCPC, FRCA Addenbrookes Hospital Cambridge, United Kingdom
Randolph H. Steadman, MD University of California, Los Angeles Los Angeles, CA, USA
John R. Lake, MD University of Minnesota Medical School Minneapolis, MN, USA
Scope Committee Ronald W. Busuttil, MD, PhD University of California, Los Angeles Los Angeles, CA, USA
Michael A.E. Ramsay, MD Baylor University Medical Center Dallas, TX, USA
Geoffrey McCaughan, MD, PhD Royal Prince Alfred Hospital Sydney, Australia
Journal Editors John R. Lake, MD University of Minnesota Medical School Minneapolis, MN, USA
John P. Roberts, MD University of California, San Francisco San Francisco, CA, USA
Committee Chairs Education Committee Chair Patrizia A. Burra, MD, PhD University di Padova Padova, Italy
Membership Chair Sung-Gyu Lee, MD Asan Medical Center Seoul, Korea
Basic Science Committee Chair Anil Dhawan, MD Kings College Hospital London, United Kingdom
Pediatric Committee Chair Sue V. McDiarmid, MD University of California, Los Angeles Los Angeles, CA, USA
Vanguard Committee Chair Constantino Fondevila, MD, PhD University of Barcelona Barcelona, Spain
Development Committee Chair John R. Lake, MD University of Minnesota Medical School Minneapolis, MN, USA
Website Committee Chair John R. Klinck, MD, FRCPC, FRCA Addenbrookes Hospital Cambridge, United Kingdom
4 S4
2012 Congress Program Committee
Program Chair
Program Co-Chair
Richard B. Freeman, Jr., MD Dartmouth School of Medicine Lebanon, NH, USA
Claus Niemann, MD University of California, San Francisco San Francisco, CA, USA
Local Program Chair
Program Co-Chair
Nancy L. Ascher, MD, PhD University of California, San Francisco San Francisco, CA, USA
Peter Stock, MD, PhD University of California, San Francisco San Francisco, CA, USA
Program Co-Chair
Program Co-Chair
Carlos Esquivel, MD, PhD Stanford University Medical Center Palo Alto, CA, USA
Norah Terrault, MD University of California, San Francisco San Francisco, CA, USA
Program Co-Chair
Vanguard Committee Chair
Ryutaro Hirose, MD University of California, San Francisco San Francisco, CA, USA
Constantino Fondevila, MD, PhD University of Barcelona Barcelona, Spain
ILTS Congress Headquarters 15000 Commerce Parkway, Suite C Mt. Laurel, NJ 08054 United States Telephone: 856-439-0500 Fax: 856-439-0525 www.ilts.org
5 S5
Acknowledgement The ILTS would like to thank the following companies for support of the Congress with unrestricted educational grants (at time of printing):
Superstar Level
Four Star Level
Two Star Level
One Star Level
6 S6
General Information Who Should Attend The 18th Annual International Congress of the International Liver Transplantation Society is the leading educational Congress for scientists, surgeons, anesthesiologists, physicians, nurses, and organ procurement personnel in the field of liver transplantation around the world. The Congress is designed to allow the liver transplantation specialist to interact and network with individuals from various parts of the globe and to compare and understand the differences in procedures and therapy in the treatment of liver transplantation. Goals & Objectives 1. To review the most innovative treatment for HCV prior to and following liver transplantation. 2. To evaluate the most current data regarding the optional treatment of HCC. 3. To define optional standards of care in liver transplantation worldwide. 4. To explore the applicability of expanding regionalization of liver distribution. 5. To promote understanding of latest surgical techniques. 6. To highlight the current state of the art management in preventing recurrent disease specifically in children. 7. To promote the interest and encourage best practices among young members and to recognize and reward talented young investigators. 8. To enhance the dialogue between clinicians and scientists on topics related to RNA mechanisms of liver allograft rejection and tolerance. 9. To provide a scientific and educational exchange for hepatologists, surgeons, intesivists, and transplant coordinators around the world.
AMA PRA Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Institute for the Advancement of Human Behavior (IAHB) and the International Liver Transplantation Society (ILTS). The IAHB is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement The IAHB designates this live activity for a maximum of 22.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME Certificates/Evaluations Your opinion is important to the program committee. CME certificates and evaluations can be submitted online. This information can be found by visiting www.ilts.org after the meeting. Scientific Program All sessions, unless otherwise noted, will take place at the Hilton San Francisco Hotel. Abstracts Abstracts selected for the Congress will be presented in plenary, concurrent, interactive, and poster sessions that will highlight the most outstanding papers from liver transplant specialties. All abstracts are published in the official Congress program book, a supplement to the ILTS/AASLD journal, Liver Transplantation.
7 S7
Poster Sessions The Poster Sessions are an important educational event of this Congress. We hope you support and attend these scientific presentations. All poster presentations are located in Grand Ballroom B, on the (GB) Grand Ballroom Level of the Hilton San Francisco Hotel. Poster presentations have been listed in numerical order per the numerical order of printed abstracts in this program book.
• Featured Symposia
Thursday, May 17, Friday, May 18 and Saturday, May 19 The program committee has developed multiple program topics that will be discussed in the Featured Symposia sessions. The committee has invited liver transplantation experts from across the globe to present on topics addressing Hepatitis C, Advances in HCC Treatment, Anesthesia/Critical Care Medicine, Biomarkers, Donor Quality, Recurrent Disease, and Disease Transmission. All program topics can be found in the Scientific Program.
Registration All attendees must be registered for the Congress. You are required to wear your badge to move in and out of sessions. Registration is located in the Yosemite Ballroom, on the (BR) Ballroom level of the Hilton San Francisco Hotel. Registration hours are listed in the Schedule of Activities, page 3.
• Vanguard Grand Rounds Case
Presentations Thursday, May 17, 6:30 am – 8:00 am This morning session will involve several presentations of interesting or difficult cases by a Vanguard Committee member to a senior ILTS participant. After comments from the senior member, the audience is encouraged to participate in a lively and informal open discussion. Case presentations will focus on Patient with Cirrhosis and Moderate Portopulmonary Hypertension, Hepatitis C Recurrence or Acute Cellular Rejection, and Prevention and Management of HCC Recurrence after Liver Transplantation. *Registration to attend this session is complimentary, and is limited to the first 200 registrants.
Session Descriptions • State-of-the-Art Lectures Thursday, May 17 and Friday May 18, 9:40 am – 10:10 am This year there will be two State-of-the-Art Lectures. Jeffrey Bluestone, PhD, Director, UCSF Diabetes Center & the Immune Tolerance Network, will give a presentation on Thursday, May 17th, 9:40 am – 10:10 am, titled “Exploiting Immune Tolerance in the Treatment of Liver Disease”. Lewis L. Lanier, PhD, from the University of California, San Francisco, will give a presentation on Friday, May 18th, 9:40 am – 10:10 am, titled “NK Cells and the Liver”.
8 S8
• Vanguard Debates
The young investigator will follow with an 8-minute presentation of the data submitted in the abstract. There will be 8 minutes allotted for discussion. *The Rising Star Symposium is supported by an unrestricted educational grant from Novartis Pharma AG.
Friday, May 18, 6:30 am – 8:00 am This morning session will involve three debates over controversial topics between a Vanguard Committee member and a senior ILTS participant. Debate topics will include Artificial Liver Support in Acute Liver Dysfunction, the Donor Risk Index as an Integral Component of Donor Selection, and Universal Induction Therapy in Liver Transplantation. *Registration to attend this session is complimentary, and is limited to the first 200 registrants.
• Interactive Oral Abstract Sessions
Thursday, May 17 and Friday, May 18, 4:30 pm – 6:15 pm This will be the first year for the NEW Interactive Oral Abstract Sessions. These sessions will be focused around a critical thematic question facing liver transplantation today. Submitted abstracts have been grouped together for presentation around these “theme” questions that address some aspect of these individual questions. The format for these sessions will be to have one of the two assigned moderators provide a brief background introduction as to the significance of the general thematic question for that session. At the end of this 10 minute presentation, this moderator will then pose 3 4 specific questions under the theme question that are answerable either as yes/no, true/ false, or multiple choice so that we can invite the audience to respond using an Audience Response System. Following the introduction, the selected abstracts will be presented in the usual 8 minute presentation, 2 minute for questions format. Once the abstracts are presented, the second moderator will have 10 minutes to provide closing information & overview, pose the same audience response questions that were presented by the first moderator questions again, and allow the audience to recast their votes. The final 15 minutes will allow for a discussion of the audience’s change in voting pattern (if any) and any other pertinent issues.
• Plenary Abstract Sessions
Thursday, May 17, Friday, May 18, and Saturday May 19, 8:00 am – 9:40 am The Plenary Sessions are submitted abstract sessions. The program planning committee has selected the best rated abstracts to be presented in the Plenary Sessions. Don’t miss the opportunity to learn about the latest research being done across the world in liver transplantation. • Rising Star Symposium*
Thursday, May 17, 10:30 am – 12:30 pm The Rising Star Symposium is a submitted abstract session. The goal of this symposium is to attract the brightest and best combinations of youth and wisdom working in clinical and basic science of liver transplantation research today. The symposium is designed to encourage young investigator/mentor teams to submit abstracts. The program planning committee has selected six young investigator/mentor teams, and the teams each give a joint 20 minute presentation. The mentor will give a 4-minute presentation of the background information and previous data relevant to the topic. The objective of the mentor’s presentation is to educate the Congress attendees on the importance and relevance of the work to be presented.
9 S9
• Concurrent Oral Abstract Sessions
Thursday, May 17, 2:30 pm – 4:00 pm, 4:30 pm – 6:15 pm; and Friday, May 18, 1:15 pm – 2:15 pm, 2:30 pm – 4:00 pm The Concurrent Oral Sessions are submitted abstract sessions. The program planning committee has selected specific abstracts, and grouped them into specific topic driven concurrent sessions. Each selected abstract presentation will consist of an 8 minute oral presentation given by one of the abstract authors, followed by 2 minutes for audience questions. These sessions will allow participants the opportunity to learn various new insights in a multitude of areas all pertaining to liver transplantation. • Poster Sessions
The Poster Sessions are submitted abstract sessions. The program planning committee has selected abstracts to be presented in poster format. Posters are viewable during open exhibit hours, and presenters will be attendance during the following dates/times: Session I: Wednesday, May 16 Session II: Thursday, May 17 Session III: Friday, May 18
Cyber Café There are complimentary e-mail stations located in the Yosemite Ballroom and West Lounge, on the (BR) Ballroom Level of the Hilton San Francisco Hotel. Please note - you are limited to 15 minutes per session. The Cyber Café is supported by an unrestricted educational grant from Astellas. Speaker Slide Check-in Room The Speaker Slide Check-in Room is located in the Yosemite Ballroom, on the (BR) Ballroom Level of the Hilton San Francisco Hotel. The Speaker Slide Check-in Room is provided for presenters to prepare for their presentations and ensure a seamless integration of a wide variety of audiovisual technologies in various meeting rooms. All speakers are required to use PowerPoint presentations; it is extremely important that speakers allow sufficient time for checking into the Speaker Slide Check-in Room. All speakers must check into the Speaker Slide Check-in Room. • All PowerPoint presentations need to be checked into the Speaker Slide Check-in Room at least 3 hours before your session begins.
5:30 pm – 7:00 pm 10:10 am – 10:30 am 4:00 pm – 4:30 pm
• Personnel in the Speaker Slide Check-in Room are available to assist with any last minute changes and to troubleshoot any problems presenters may have.
10:10 am – 10:30 am 4:00 pm – 4:30 pm
• Submitted Video Session
Friday, May 18, 1:15pm -2:15pm For the fourth year in a row, Congress participants have been given the opportunity to submit liver transplantation surgical videos for presentation. The program planning committee has selected videos to be presented during one of the concurrent oral abstract time slots.
• Presenters will have their presentation electronically queued from the Speaker Slide Check-in room to the meeting room. By checking in at the Speaker Slide Check-in Room and following these simple guidelines, speakers greatly contribute to the success of the Congress. The Speaker Slide Check-in Room hours are located in the Schedule of Activities page 3.
10 S10
Congress Location Hilton San Francisco Union Square Hotel The Hilton San Francisco Union Square Hotel will host this year’s Congress. Located right in the center of downtown San Francisco, the Hilton offers an ideal setting in the heart of one of California’s most unique cities. The historic Hilton is one of the largest and tallest hotels on the West Coast, offering exquisite views of the city and easy access to all San Francisco has to offer. Hilton San Francisco Union Square Hotel 333 O’Farrell Street San Francisco, CA, 94102 USA Social Activities Opening Reception Wednesday, May 16, 2012 5:30 pm – 7:00 pm Grand Ballroom B, (GB) Grand Ballroom Level The Opening Reception will take place during the Opening of Exhibits. All registered attendees are able to attend this event.
Taking Asian cosmology and spirituality as its theme, Phantoms of Asia seeks to rediscover invisible interconnectivity through the histories, cultures, and religions of all of Asia. Works from the Asian Art Museum’s collection of traditional art will be juxtaposed with contemporary works – not merely in attempt to compare the past and present, but also to expand our imagination beyond space and time to include the spiritual world and the afterlife, as well as to examine the ancestry of contemporary perspectives of the universe. The result will be an opportunity to reconsider the concept of “pan-Asia” beyond a political and economic entity: as interconnected “phantoms” of invisible spiritual energy. *This is a ticketed reception. Entry will only be granted to attendees that purchase tickets in advance in addition to Congress Registration. No entry is permitted without a ticket. Transportation will be provided.
Congress Reception* Friday, May 18, 2012 7:30 pm – 10:30 pm Offsite – Asian Art Museum Join your fellow Congress attendees at the “Phantoms of Asia: Contemporary Awakens the Past” Congress Closing Reception being held at the Asian Art Museum. ILTS Congress attendees will be the FIRST to enter this brand new exhibit.
11 S11
Distinguished Service Award Winners Anthony J. Demetris, MD University of Pittsburgh Medical Center Pittsburgh, PA, USA and Henri Bismuth, MD, FACS (Hon.) Hospital Paul Brousse Villejuif, France
The Distinguished Service Awards will be presented on Friday, May 18, 12:15 PM – 1:00 PM, in Continental Ballroom, on the (BR) Ballroom Level of the Hilton San Francisco Union Square Hotel.
Vanguard Award Winners Armin Göttingen, MD University Medical Center Göttingen Göttingen, Germany and Naohisa Kuriyama, MD Mie University Graduate School of Medicine Tsu, Mie, Japan The Vanguard Awards will be presented during the Vanguard Reception on Thursday, May 17, 6:30 PM – 7:30 PM, in the Cityscape Room, on the 46th level of the Hilton San Francisco Union Square Hotel.
12 S12
Rising Star Awards* * Supported by an Unrestricted Educational Grant from Novartis Pharma AG. The Rising Star Awards are given to the best combinations of youth and wisdom working in the clinical and basic science of liver transplantation research today. This award is based upon abstract submissions by a young investigator and their designated mentor. Rising Star Award winner presentations will take place on Thursday, May 17, 10:30 AM – 12:30 PM, in Continental Ballroom, (BR) Ballroom Level of the Hilton San Francisco.
Team # 1
Team # 4
(Abstract #O-11) Uta Herden, MD -Young Investigator University Medical Center Hamburg-Eppendorf Harburg, Germany
(Abstract #O-14) Audrey Coilly, MD -Young Investigator AP-HP Hopital Paul Brousse Villejuif, France
Lutz Fischer, MD -Mentor University Medical Center Hamburg-Eppendorf Harburg, Germany
Jean-Charles Duclos-Vallee, MD -Mentor AP-HP Hôpital Paul Brousse Villejuif, France
Team # 2
Team # 5
(Abstract #O-12) Kirk Giesbrandt, MD -Young Investigator Mayo Clinic Rochester, MN, USA
(Abstract #O-15) Paolo Salvalaggio, MD -Young Investigator Hospital Israelita Albert Einstein São Paulo, Brazil
Burcin Taner, MD -Mentor Mayo Clinic Rochester, MN, USA
Ben-Hur Ferraz-Neto, MD, PhD, FEBS -Mentor Hospital Israelita Albert Einstein São Paulo, Brazil
Team # 3
Team # 6
(Abstract #O-13) Ricardo Gehrau, PhD -Young Investigator Virginia Commonwealth University Richmond, VA, USA
(Abstract #O-16) Xiaobo Yu, PhD -Young Investigator Zhejiang University Hangzhou, China
Valeria Mas, PhD -Mentor Virginia Commonwealth University Richmond, VA, USA
Shusen Zheng, MD, PhD -Mentor Zhejiang University Hangzhou, China
13 S13
Young Investigator Award Winners Axel Andres, Abstract # O-3 A Score Predicting Survival after Retransplantation for Hepatitis C Virus Cirrhosis.
Amr Yassen, Abstract # O-79 Right Ventricular End Diastolic Volume as a Guide for Fluid Resuscitation Compared to Central Venous Pressure in Living Donor Liver Transplantation. A Randomized Controlled Trial.
M. Platto, Abstract # O-5 223 Consecutive Liver Transplants in Children Using a Split Graft: A Single Centre Experience.
Zhiyong Guo, Abstract # O-81 Can Immune Cell Function Assay Identify Patients at Risk of Infection or Rejection? A Meta-Analysis.
Yoichiro Uchida, Abstract # O-7 Is It Possible To Wean Immunosuppression in Pediatric Liver Transplantation? The Problem of Long-Term Management. Andrei Minou, Abstract # O-10 Preconditioning with Sevoflurane Decreases the Incidence of Early Allograft Dysfunction in Liver Transplant Recipients of Steatotic Grafts. Hugo Kaneku, Abstract # O-18 Induction Therapy Decreases the Risk of Rejection after Liver Transplantation in Patients with Preformed Donor-Specific HLA Antibodies. Noriyo Yamashiki, Abstract # O-35 Outcome of Liver Transplantation for Acute Liver Failure in Japan; the Results from a Nationwide Survey. C. Verhoeven, Abstract # O-38 MicroRNA Profiles in Graft Preservation Solution Predict Biliary Complications after Liver Transplantation. Justin Parekh, Abstract # O-40 The Prevalence of Diabetes, Hypertension, and Hyperlipidemia over Time after Liver Transplantation and Their Impact on Long Term Survival.
Jacqueline O’Leary, Abstract # O-82 De Novo MHC Class II Antibody Formation Impairs Graft and Patient Survival after Liver Transplantation. Juan Gallegos-Orozco, Abstract # O-83 Magnetic Resonance Elastography (MRE) Can Discriminate Normal vs. Abnormal Liver Biopsy in Candidates for Live Liver Donation. Amardeep Yadav, Abstract # O-121 How Good Is Pre-Operative CT Volumetry for Right Lobe, Left Lobe and Left Lateral Sector Liver Grafts? James Fung, Abstract # O-126 Entecavir Versus Lamivudine Prophylaxis without Hepatitis B Immune Globulin after Liver Transplantation for Chronic Hepatitis B K.T. Ng, Abstract # O-128 Acute Phase Circulating micoRNAs Predict Tumor Recurrence and Survivals of Hepatocellular Carcinoma Patients after Liver Transplantation.
14 S14
Quirino Lai, Abstract # O-151 HCC Recurrence after Liver Transplantation in Asia and Europe: Different Biology or Different Management?
Raviraj Raveendran, Abstract # O-172 Liver Transplantation Using Marginal Donors – An Outcome Study of Canadian System.
David Goldberg, Abstract # O-163 Increasing Disparity in Waitlist Mortality Rates with Increased MELD Scores for Candidates with Versus without Hepatocellular Carcinoma. Cigdem Arikan, Abstract # O-166 Sirolimus in Pediatric Liver Transplantation: A Single-Center Experience. Mikram Jafri, Abstract # O-167 Transdermal Rivastigmine for Treatment of Encephalopathy in Liver Cirrhosis – A Randomized Placebo Controlled Trial (TREC Trial). Y.Y. Ma, Abstract # O-170 Novel Mechanism for Tissue Repair of Human Induced Pluripotent Stem Cells Derived Mesenchymal Stem Cells during Liver Regeneration.
Elke Eggenhofer, Abstract # O-171 The Role of RORγt+ T17 Cells in Hepatic Ischemia Reperfusion Injury.
Gi-Won Song, Abstract # O-173 Three-Year Experience of ABOIncompatible Adult Living Donor Liver Transplantation in Single Center: No Immunological Failure with Consecutive 80 Cases under Rituximab Prophylaxis. Milljae Shin, Abstract # P-65 Significance of Pretransplant False Positive Lymphocytotoxic Crossmatch in Liver Transplantation. Ching-Di Chang, Abstract # P-119 Significance of Portal Venous Pressure in Adult Living Donor Liver Transplantation.
15 S15
Travel Grant Awards Giriraj Bora, Abstract# O-30 Corrected Portal Pressure of > 15mmHg Correlates with Early Graft Dysfunction While Absolute Portal Pressure Doesn’t.
Bjiorn Lien, Abstract# O-62 Choledochoduodenostomy as Biliary Reconstruction in Liver Transplantation.
Rahul Kakodkar, Abstract# O-31 Accessory Hepatic Vein Reconstruction in Right Lobe Living Donor Liver Transplantation: Will near Infra-Red Spectroscopy with Indo-Cyanine Green Set New Paradigms? Prashant Bhangui, Abstract# O-36 An 8 Year Experience with Living Donor Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients: Should We Stick to Conventional Criteria? Fabrizio Di Benedetto, Abstract# O-39 Multicentric North-Italian Experience in Liver Transplantation for Hepatocellular Carcinoma in HIV Co-Infected Patients.
Amit Rastogi, Abstract# O-64 Live Donor Hepatectomy Using Midline Incision: India’s First Series. Kyota Fukazawa, Abstract# O-87 Size Adjusted Peak Aspartate Aminotransferase (ASTi) Has Better Predictive Value for Primary Graft Non-Function (PNF) Than Conventional UNOS Criteria in Orthotopic Liver Transplantation (OLT). Daniel Foltys, Abstract# O-150 Surgery of Hepatocellular Carcinoma in Cirrhosis: Liver Resection Versus Liver Transplantation. Francesco D'Amico, Abstract# O-122 Alphafetoprotein and Transplant Survival Benefit for Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study
Seung Duk Lee, Abstract# O-41 Safety of Graft-to-Recipient Weight Ratio 15mmHg Correlates with Early Graft Dysfunction While Absolute Portal Pressure Doesn’t. (Abstract # O-30) Giriraj Singh Bora, K. R. Vasudevan, Manav Wadhawan, Shaleen Agarwal, Ramdeep Ray, Shishir Pareek, Neerav Goyal, Abheedeep Chaudhary, Sunil Taneja, Subash Gupta. New Delhi, India. Accessory Hepatic Vein Reconstruction in Right Lobe Living Donor Liver Transplantation: Will near Infra-Red Spectroscopy with Indo-Cyanine Green Set New Paradigms? (Abstract # O-31) Rahul Kakodkar, Puneet Singla, Ravi Mohanka, Amit Rastogi, Sanjay Goja, P. Balachandran, Sanjiv Saigal, Neeraj Saraf, Arvinder Soin. Gurgaon, Haryana, India.
3:20 PM
Is Right Liver Donation in Living Donor Liver Transplantation Really Safe Procedure? (Abstract # O-32) Say June Kim, Dong Goo Kim, Kun Hyung Na, Ho Jung Choi, Yung Kyung Yoo, Tae Ho Hong. Seoul, Korea.
3:30 PM
Portacaval Shunt Blood Flow during Anhepatic Phase Adequately Predicts Portal Vein Flow at Reperfusion during Living Donor Liver Transplantation. Clinical Implications. (Abstract # O-33) Santiago Sánchez Cabús, David Calatayud, Joana Ferrer, Mihai C. Pavel, Javier Melchor, Josep Martí, Josep Fuster, Constantino Fondevila, Juan Carlos García-Valdecasas. Barcelona, Spain.
3:40 PM
Increasing the Recipient-Benefit to Donor-Risk Ratio by Lowering the Graft Size Requirement for Living Donor Liver Transplantation. (Abstract # O-34) See C. Chan, Kenneth S. Chok, William Sharr, Albert C. Chan, Wing C. Dai, Sheung T. Fan, Chung M. Lo. Hong Kong, Hong Kong.
3:50 PM
Outcome of Liver Transplantation for Acute Liver Failure in Japan; the Results from a Nationwide Survey. (Abstract # O-35) Noriyo Yamashiki, Yasuhiko Sugawara, Sumihito Tamura, Nobuaki Nakayama, Makoto Oketani, Koji Umeshita, Shinji Uemoto, Satoshi Mochida, Hirohito Tsubouchi, Norihiro Kokudo. Tokyo, Japan; Saitama, Japan; Kagoshima, Japan; Osaka, Japan; Kyoto, Japan.
S25
2:30 PM
An 8 Year Experience with Living Donor Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients: Should We Stick to Conventional Criteria? (Abstract # O-36) Prashant Bhangui, Rahul Kakodkar, Ravi Mohanka, Amit Rastogi, Sanjay Goja, P. Balachandran Menon, Sanjiv Saigal, Arvinder Soin. Delhi NCR, India.
2:40 PM
Preformed MHC Class II Antibodies Increase the Risk of Liver but Not Kidney Rejection after Simultaneous Liver-Kidney Transplant. (Abstract # O-37) Jacqueline G. O’Leary, Howard M. Gebel, Richard M. Ruiz, Robert A. Bray, John D. Marr, Brian M. Susskind, Allan D. Kirk, Goran B. Klintmalm. Dallas, TX, USA; Atlanta, GA, USA.
2:50 PM
MicroRNA Profiles in Graft Preservation Solution Predict Biliary Complications after Liver Transplantation. (Abstract # O-38) C. J. Verhoeven, W. R.R. Farid, P. E. de Ruiter, J. de Jonge, J. Kwekkeboom, H. J. Metselaar, H. W. Tilanus, G. Kazemier, L. J.W. van der Laan. Rotterdam, Netherlands.
3:00 PM
Multicentric North-Italian Experience in Liver Transplantation for Hepatocellular Carcinoma in HIV Co-Infected Patients. (Abstract # O-39) Fabrizio Di Benedetto, Giuseppe Tarantino, Roberto Montalti, Giuseppe D’Amico, Umberto Baccarani, Marcello Tavio, Stefania Cocchi, Giorgio Ercolani, Matteo Zanello, Gian Luigi Adani, Antonio D. Pinna, Giorgio E. Gerunda. Modena, Italy; Udine, Italy; Ancona, Italy; Bologna, Italy.
3:10 PM
The Prevalence of Diabetes, Hypertension, and Hyperlipidemia over Time after Liver Transplantation and Their Impact on Long Term Survival. (Abstract # O-40) Justin Parekh, Doug Corley, Sandy Feng. CA, USA; Oakland, CA, USA.
3:20 PM
Safety of Graft-to-Recipient Weight Ratio 30 Points) – Single-Centre Results and Re-Evaluation of Prognostic Models for Postoperative Survival (Abstract # LB61) Christoph Benckert, Markus Quante, Armin Thelen, Udo Kaisers, Sven Berker, Thomas Berg, Sven Jonas. Leipzig, Germany.
LB62
Increased Morbidity in Overweight and Obese Liver Transplant Recipients – A Single Centre Experience with 1325 Patients (Abstract # LB62) Abdul Hakeem, Soulat Raza, Niaz Ahmad, K. Raj Prasad, Krishna Menon. Leeds, United Kingdom.
LB63
Liver Transplantation Using Donation after Cardiac Death Donor – A Pediatric Liver Donor to Adult Recipient. A Case Report (Abstract # LB63) Zhijun Zhu, Wei Gao, Chong Dong, Lin Wei, Liying Sun, Tao Yang. Tian Jin, China.
LB64
Is Routine Sternotomy Necessary for Organ Recovery from Deceased Donors? A Comparative Retrospective Study (Abstract # LB64) Mehmet Yilmaz, Sami Akbulut, Turgut Piskin, Fatih Gonultas, Veysel Ersan, Sezai Yilmaz. Malatya, Turkey; Diyarbakir, Turkey.
LB65
Non-Invasive Measurement of the Portal Circulation Using Cholates Quantifies Disease Severity in Waiting List Patients with Primary Sclerosing Cholangitis (Abstract # LB65) Steve M. Helmke, Ariana Wallack, Andrea Herman, Shannon Lauriski, Gregory T. Everson. Aurora, CO, USA.
LB66
Twelve Years Follow-Up of Two Cases in One Family of Living Donor Liver Transplantation for Homozygous Familial Hypercholesterolemia (Abstract # LB66) Naoki Kawagishi, Ikuo Takeda, Shigehito Miyagi, Kazushige Satoh, Satoshi Sekiguchi, Susumu Satomi. Sendai, Japan.
LB67
Hypogammaglobulinemia in the Early Post Liver Transplantation Period in Children (Abstract # LB67) Yael Mozer-Glassberg, Ran Stainberg, Raanan Shamir, Efrat Har-Lev, Eitan Mor, Rivka Shapiro, Tommy Schonfeld, Elhanan Nahum. Petha-Tikva, Israel; Tel-Aviv, Israel.
LB68
The Development of De-Novo Autoimmune Hepatitis Predicts Inferior Long-Term Outcomes among Pediatric Liver Transplant Recipients (Abstract # LB68) Robert S. Venick, Sue V. McDiarmid, Susan Feist, Jorge H. Vargas, Douglas G. Farmer, Ronald W. Busuttil. Los Angeles, CA, USA; Los Angeles, CA, USA.
LB69
Report of Intravenous Fish Oil for the Treatment of Post-Transplant Pediatric Intestinal Failure Associated Liver Disease (Abstract # LB69) Kara Calkins, Stephen Shew, James Dunn, Douglas G. Farmer, Sue V. McDiarmid, Ronald W. Busuttil, Robert S. Venick. Los Angeles, CA, USA; Los Angeles, CA, USA.
Radiology LB70
S66
Budd Chiari Syndrome Secondary to Compressive Effect of Giant Hydatid Cyst (Abstract # LB70) Mehmet Yilmaz, Fatih Ozdemir, Sami Akbulut, Aysegul Kahraman, Sezai Yilmaz. Malatya, Turkey; Diyarbakir, Turkey.
P-288
The Successful Use of Methylene Blue for Treatment of Vasoplegic Syndrome in an Immunosuppressed Patient after Liver Transplant. (Abstract # P-288) Saravanan Ramamoorthy, Shachi Patel, Eric Bradburn, Tadahiro Uemura, Zakiyah Kadry, Piotr Janicki, Dmitri Bezinover. Hershey, PA, USA.
P-289
Postreperfusion Hyperglycemia May Be Indicative of Improved Graft Quality in Adult Whole Liver Transplantation. (Abstract # P-282) J. Beltran, C. Fondevila, A.J. Hessheimer, E. Flores, G. Martinez-Pallí, A. Blasi, J. Balust, P. Taurà, J.C. García-Valdecasas. Barcelona, Spain.
A Case of Intraoperative Paradoxical Air Embolism, without Any Identification of an Intra-Cardiac Shunt, in a Patient Undergoing Orthotopic Liver Transplantation for Hepatitis C Cirrhosis. (Abstract # P-289) Asim N. Iqbal, Suresh Vasanth, Scott Russell, John Isaac, Gareth Jeskins, Adam Hill. Birmingham, United Kingdom.
P-290
Intraoperative Blood Pressure Variability in Liver Transplantation. (Abstract # P-282_A) Samuel DeMaria, Johannes Nurnberg, Alan Sim, Daniel Groth, Kenneth Flax, John Vullo, Juan Rocca, Sander Florman, Alan Contreras, David Reich. New York, NY, USA.
Renal Function Profile after Liver Transplant. (Abstract # P-290) Dirk Schreen, Maria Cristina L.A. Borges, Maria Ozilene R. Batista, Ana Maria M. Rodrigues, Ocilia M.C. Carvalho, Emmanuel A. Nogueira, José Huygens P. Garcia. Fortaleza, Ceará, Brazil.
P-291 †
Determination of Quantitative Platelet and Fibrinogen Levels in Patients Using Rotational Thromboelastometry (ROTEM®) Parameters during Liver Transplantation. (Abstract # P-283) Bo-Hyun Sang, Jun-Gol Song, Sung-Moon Jeong, Gyu-Sam Hwang. Seoul, Republic of Korea.
The Use of Optic Nerve Ultrasound To Monitor Elevations in ICP in Acute Liver Failure Requiring Liver Transplantation. (Abstract # P-291) Vijay Krishnamoorthy, Katharina Beckmann, Mark Mueller, David Schwartz. IL, USA.
Basic Sciences
Room: Grand Ballroom B, (GB) Grand Ballroom Level † Those posters identified as a Poster of Distinction by this symbol have received review scores that place them in the top 10% of their category. The Planning Committee encourages you to make them a priority when you visit the poster session.
Anesthesia/Critical Care Medicine P-282
P-282_A
P-283
P-284
Metabolic Acidosis in Patients Undergoing Donor Hepatectomy with or without Inclusion of Middle Hepatic Vein. (Abstract # P-284) Sanjeev Aneja, Asish Malik. New Delhi, Delhi, India.
P-285
Inmediate Extubation in Adults Undergoing Liver Transplantation: Its Impact on Postoperative Mortality. (Abstract # P-285) Maria M. Anders, Pablo D. Comignani, Jose Mella, Gustavo Devetach, Lucio Koo, Carlos Jeanes, Federico Orozco, Ariel Sosa, Javier Osatnik, Rocio Couce, Mariano Santopinto, Nadia Prini, Nicolas Goldaracena, Emilio Quiñonez, Lucas McCormack, Ricardo Mastai. Buenos Aires, Argentina.
P-286
Characteristics of Hemodynamic Profiles in ReDo Liver Transplantation. (Abstract # P-286) Krishnan Rao, Zoka Milan, Charles Taylor, John McElwaine, Mark Bellamy. Leeds, United Kingdom.
P-287
Perioperative Coagulation in Liver Transplantation for Congenital Factor VII Deficiency. (Abstract # P-287) Nikunj Gupta, Annu Sarin Jolly, G.V. Premkumar, Seema Bhalotra, Vijay Vohra. Gurgaon, Haryana, India.
S67
P-292 †
Efficacy and Safety of Subcutaneous Administration of Hepatitis B Immunoglobulines in 137 Liver Transplant Recipients. (Abstract # P-292) Michele Imparato, Carla Migliaccio, Alfonso Galeota Lanza, Giuseppe Surfaro, Francesco Paolo Picciotto, Marina Romano, Antonio Giuliani, Giovanni Giuseppe Di Costanzo, Fulvio Calise. Naples, Italy.
P-293 †
Induction of Autoimmune Hepatitis Paradoxically Reduce the Rejection after Liver Transplantation in Rats. (Abstract # P-293) Chia-Yun Lai, Toshiaki Nakano, Shigeru Goto, Yen-Chen Chang, Li-Wen Hsu, Kuang-Den Chen, Chih-Che Lin, Chih-Chi Wang, Yu-Fan Cheng, Chao-Long Chen. Kaohsiung, Taiwan; Yufu, Oita, Japan.
P-294
Immunological and Regenerative Aspects of Hepatic Mast Cells in Liver Allograft Rejection and Tolerance. (Abstract # P-294) Toshiaki Nakano, Shigeru Goto, Chia-Yun Lai, Li-Wen Hsu, Kuang-Den Chen, Chih-Che Lin, Chih-Chi Wang, Yu-Fan Cheng, Chao-Long Chen. Kaohsiung, Taiwan; Yufu, Oita, Japan.
Poster Session III
POSTER SESSION III 10:10 AM – 10:30 AM & 4:00 PM – 4:30 PM
P-295
Coagulation Factor VII Expression Predicts the Vascular Invasion in Human Hepatocellular Carcinoma. (Abstract # P-295) Chih-Che Lin, Hsiang-Jen Yang, Li-Yu Chen, ChihChi Wang, Kuang-Den Chen, Toshiaki Nakano, Shigeru Goto, Chao-Long Chen. Kaohsiung, Taiwan; Oita, Japan.
P-296
Treatment with DPP-IV Inhibitor and G-CSF May Enhance Mobilization of Host Stem Cells and Contribute To Overcome Small-for-Size Graft Syndrome. (Abstract # P-296) Shigeru Goto, Li-Wen Hsu, Yen-Che Chang, Toshiaki Nakano, Kuang-Den Chen, Chia-Yun Lai, Chih-Chi Wang, Yu-Fan Cheng, King-Wah Chiu, Chih-Che Lin, Chao-Long Chen. Kaohsiung, Taiwan.
P-297
The Role of Fibroblast Growth Factor 15 during Liver Regeneration after Partial Hepatectomy in Mice. (Abstract # P-297) Qiang Li, Xiaofeng Zhu, Xiaoshun He, Zhiyong Guo, Fei-wen Deng, Jie Ouyang. Guangzhou, Guangdong, China.
P-298
MDSCs Enhance the Function of Treg Cells in Immune Regulation after Mouse MHCMismatch Liver Transplantation. (Abstract # P-298) Yan Wang, Fei Sun, Jie Xiang, Xiang Zheng, Shusen Zheng. Hangzhou, Zhejiang, China.
P-299
HMGB1 Expression Is Prevented in Steatotic and Non Steatotic Liver Grafts Preserved in IGL-1 Solution: A Role for PPAR-gamma. (Abstract # P-299) Eirini Pantazi, Mohamed Amine Zaouali, Mohamed Bejaoui, Judit Garcia-Villoria, Antonia Ribes, Hassen Ben Abdennebi, Joan Rosello-Catafau. Barcelona, Spain; Monastir, Tunisia.
P-300
Relevance of Glucogen Synthase Kinase-3Beta and Voltage-Dependant Anion Channels in Orthotopic Liver Transplantation: An IGL-1 Solution Approach. (Abstract # P-300) Mohamed Bejoaui, Mohamed Amine Zaouali, Alexandre Lopez, Eirini Pantazi, Hassen Ben Abdennebi, Joan Roselló-Catafau. Barcelona, Spain; Monastir, Tunisia.
P-301
Gene Expression Profile Involved in Liver Preservation Model Using Third-Generation Perfluorocarbons by Microarray Analysis. (Abstract # P-301) S. Ramamoorthy, S. Mahmoud, D. Bezinover, G. Weller, T. Uemura, Z. Kadry, P. Janicki. Hershey, PA, USA.
P-302
Graft Liver CYP2C19 Genotypes and Post Operative Abnormal Liver Function after Living Donor Liver Transplantation. (Abstract # P-302) King-Wah Chiu, Toshiaki Nakano, Shigeru Goto, Tsung-Hui Hu, Chao-Long Chen. Kaohsiung, Taiwan.
P-303
The Inhibition of CD40-CD514 Signalling Inhibition Liver Injury In Vitro and In Vivo. (Abstract # P-303) Ricky H. Bhogal, Simon C. Afford, David H. Adams. Birmingham, West Midlands, United Kingdom.
P-304
Comparison of Prophylaxis and Preemptive Strategy as a Routine CMV Prevention of Seronegative (R-) Liver Transplant Recipients from Seropositive Donors (D+). (Abstract # P-304) Christophe Camus, Anne Le Neillon, David Veyer, Marianne Latournerie, Edouard Bardou-Jacquet, Philippe Compagnon, Karim Boudjema. Rennes, France.
P-305
The Red Wine Polyphenol Reduces the Biliary Obstructed Rats Cholestasis: The Involvement of Mitochondrial Biogenesis and Autophagy Induction. (Abstract # P-305) Mao-Meng Tiao, Chao-Long Chen, Allan Concejero, Yu-Fan Cheng. Kaohsiung, Taiwan.
P-306
HDAC Inhibitor TSA Attenuates ReducedSize Liver Ischemia-Reperfusion Injury and Promotes Liver Regeneration in Rats. (Abstract # P-306) Jun Yu, Yuanxing Liu, Xin Duan, Shusen Zheng. Hangzhou, Zhejiang, China.
P-307
The Ischemia/Reperfusion Injury of the Hepatic Graft: Gene Expression Analysis of Potentially Evolved Genes. (Abstract # P-307) Jorge Pereira, Olga Abade, Dario Ligeiro, João Sobral, Emanuel Vigia, Eduardo Barroso, Helder Trindade. Lisboa, Portugal.
P-308
The Expression of Hepatic Signal Transduction Proteins Following Reduce-Size Liver Transplantation in Rat. (Abstract # P-308) Li Li, Jing Liu, Hua Jiang Ran, Yan Xiao Li, Ning Sheng Zhang. Kunming, Yunnan, China.
Extended Criteria Donors/Disease Transmission
S68
P-309 †
Successful Organ Donation and Outcomes Following Long-Term Circulatory Support with Non-Pulsatile Mechanical Support. (Abstract # P-309) Alastair D. Smith, Meaghan L. McKinnon, Chetan B. Patel, Deepak Vikraman-Sushama, Gary M. Felker, Debra L. Sudan, Paul B. Rosenberg, Adrian F. Hernandez, Carmelo A. Milano, Joseph G. Rogers. Durham, NC, USA.
P-310
Does Liver Graft Volume Correlate to Transaminases Peak Following Whole Liver Transplantation? (Abstract # P-310) Guido Liddo, Emmanuel Boleslawski, Francois Corfiotti, Stephanie Truant, Fouad Bouras, Sebastien Dharancy, Nicole Declerck, Gilles Lebuffe, Francois-Rene Pruvot. Lille, France.
Combined ‘En Bloc’ Liver-Duodeno-Pancreatic Transplantation in Patients with End-Stage Liver Disease and Type 2 Diabetes Mellitus. (Abstract # P-311) Weiqiang Ju, Zhiyong Guo, Xiaoshun He, Maogen Chen, Ronghai Deng. Guangzhou, Guangdong, China.
P-318
Genotype 2 Is a Favorable Factor for PreTransplant Short-Term Therapy of HCV Infection in Living Donor Liver Transplantation. (Abstract # P-318) Yueh-Wei Liu, Chao-Long Chen, Chih-Che Lin, Chih-Chi Wang, Shih-Ho Wong. Kaohsiung, Taiwan.
P-312
Significance of Primary Poor Function (PPF) for the Prognosis after Liver Transplantation: A Search for the Right Definition. (Abstract # P-312) Gilles Uijtterhaegen, Ivo Haentjens, Roberto Troisi, Georges Van Maele, Hans Van Vlierberghe, Xavier Rogiers. Ghent, Belgium.
P-319
Comparative Study between Hepatitis C Virus (HCV) and Non HCV Recipients Older Than 65 Years. (Abstract # P-319) Iago Justo, Oscar Caso, Fakih Naim, Alberto Marcacuzco, Felix Cambra, Jorge Calvo, Alejandro Manrique, Alvaro Garcia, Manuel Abradelo, Sergio Olivares, Edurne Alvaro, Cristina Alegre, Maria Garcia, Rebeca Sanabria, Enrique Moreno, Carlos Jimenez. Madrid, Spain.
P-320
Bilirubin at Day 7, a Marker of Preservation Injury, Predicts a More Aggressive Hepatitis C Recurrence. (Abstract # P-320) Kavous Pakseresht, Timothy Schmitt, Mohammad Titi, Sean Kumer, Mojtaba Olyaee, Ryan Taylor, Winston Dunn, Richard Gilroy. Kansas City, KS, USA.
P-321
Recipient IL28B Gene Polymorphism and Recurrent Hepatitis C Following Liver Transplantation in Romanian Patients. (Abstract # P-321) Speranta Iacob, Razvan Iacob, Anca Nastase, Daniel Coriu, Liliana Paslaru, Irinel Popescu, Liana Gheorghe. Bucharest, Romania.
Fulminant Liver Failure P-313 †
Acute Liver Failure Admitted to the ICU: Outcome and Impact of MARS Albumin Dialysis. (Abstract # P-313) Christophe Camus, Anne Laure Malot, Arnaud Gacouin, Sylvain Lavoué, Philippe Compagnon, Karim Boudjema, Yves Le Tulzo. Rennes, France.
P-314
Online Hemodiafiltration Is a Promising Method To Give a Greater Chance of Undergoing Transplantation. (Abstract # P-314) Kazuaki Inoue, Makoto Yoshiba. Yokohama, Japan; Tokyo, Japan.
P-315
Living Donor Liver Transplantation in Comparison to Cadaveric Liver Transplantation for Acute Liver Failure. (Abstract # P-315) Mitsuru Nakatsuka, Jan Pasnak, Robert Fisher. Richmond, VA, USA.
P-316
Immunosuppression P-322 †
A Prospective Study To Evaluate Patients’ Compliance, Quality of Life and Drug Efficacy Evaluation after Conversion 1:1 from TwiceDaily to Once-Daily Tacrolimus in Liver Transplantation. (Abstract # P-322) Luca Toti, Tommaso M. Manzia, Alessandro Anselmo, Giuseppe Iaria, Laura Tariciotti, Daniele Sforza, Edoardo Ricciardi, Rosa Scaramuzzo, Roberta Angelico, Giuseppe Tisone. Rome, Italy.
P-323
The Experience of Switching to Sirolimus-Based Immune Suppression in Adults after Living Donor Liver Transplantation. (Abstract # P-323) Chih-Che Lin, Chih-Chi Wang, Shih-Ho Wang, Yueh-Wei Liu, Chee-Chien Yong, Ting-Lung Lin, Wei-Feng Lee, Yu-Hung Lin, Chao-Long Chen. Kaohsiung, Taiwan.
P-324
Initial Immunosuppression with or without Basiliximab, a Comparative Study. (Abstract # P-324) Rosa M. Martin-Mateos, Javier Graus, Miguel A. Rodriguez-Gandia, Carlos Arocena, Agustin Albillos, Carlos Blesa, Fernando Garcia-Hoz, Javier Garcia-Alonso, Ana Gonzalez-Tallon, Rafael Barcena. Madrid, Spain.
Acute Hepatic Failure Due to Celecoxib Requiring Liver Transplantation. (Abstract # P-316) Naim Fakih, Oscar Caso, Iago Justo, Sergio Olivares, Edurne Alvaro, Cristina Alegre, Rebeca Sanabria, Maria Garcia, Felix Cambra, Jorge Calvo, Alvaro Garcia, Alejandro Manrique, Manuel Abradelo, Enrique Moreno, Carlos Jimenez. Madrid, Spain.
Hepatitis C P-317
Rapid Virological Response in PBMC with an Increase of HCV-Specific IFN-αProduction Predisposes to SVR in Patients with HCV Recurrence after Liver Transplantation with Genotype 1 Undergoing Peg-IFNa2a Plus Ribavirin. (Abstract # P-317) Alessandro Perrella, Alfonso Lanza, Donatella Pisaniello, Giovanni Di Costanzo, Amadeos Marcos, Oreste Cuomo. NAples, Italy.
S69
Poster Session III
P-311
P-325
Everolimus Monotherapy in Liver Transplantation for Neuroendocrine Carcinoma. (Abstract # P-325) Jason M. Vanatta, Amanda G. Dean, Kian A. Modanlou, Satheesh Nair, Nosratollah Nezakatgoo, Luis Campos, James D. Eason. Memphis, TN, USA.
P-333
Changes in Portal Pressure Predict the Pattern of Remnant Regeneration Post Donor Hepatectomy. (Abstract # P-333) Subash Gupta, Abhishek Yadav, Neerav Goyal, Manav Wadhawan, K.R. Vasudevan. New Delhi, India.
P-326
Impact of the Conversion of the Immunsuppressive Regimen from Prograf to Advagraf or to Sirolimus in Long Term Stable Liver Transplant Recipients. Indications, Safety and Outcome. A Single Center Experience. (Abstract # P-326) Aristotelis Perrakis, Kerstin Schwarz, Roland Croner, Vera Schellerer, Clemens Lohmüller, Volker Müller. Erlangen, Germany.
P-334
Splenic Artery Ligation: Still a Good Alternative for Graft Inflow Modulation. (Abstract # P-334) Santiago Sánchez Cabús, David Calatayud, Joana Ferrer, Mihai C. Pavel, Javier Melchor, Josep Martí, Josep Fuster, Constantino Fondevila, Juan Carlos García-Valdecasas. Barcelona, Spain.
P-335
The Non-Traditional Living Donor. (Abstract # P-335) Mary Ann Simpson, Denise S. Morin, Mohamed Akoad, James J. Pomposelli, Elizabeth A. Pomfret. Burlington, MA, USA.
P-336
Donor Outcomes in a Series of 524 Right Lobe Living Related Liver Transplants at a Single Centre. (Abstract # P-336) Subash Gupta, Ramdip Ray, Neerav Goyal, Manav Wadhawan. New Delhi, Delhi, India.
P-337
Graft Recipient Weight Ratio Should Not Be Included in the Definition of Small for Size Syndrome Following Live Donor Liver Transplantation. (Abstract # P-337) Karisangal R. Vasudevan, Neerav Goyal, Ramdip Ray, Shishir Pareek, Shaleen Agarwal, Abhideep Chaudhary, Rajesh Nambiar, Manav Wadhawan, Subash Gupta. New Delhi, Delhi, India.
P-338
The Impact of Hepatic Macrovesicular and Microvesicular Steatosis on the Hepatic Functions after Right Hepatectomy in Living Donors. (Abstract # P-338) Mi hye Park, Hye Won Song, Young hee Shin, Justin Sangwook Ko, Mi sook Gwak, Kaab soo Kim. Seoul, Republic of Korea.
P-339
Outcome in 75 Consecutive Pediatric Living Donor Liver Transplants. (Abstract # P-339) Neelam Mohan, Sakshi Karkra, Ravi Mohanka, A. Rastogi, R. Kakodkar, M. Balachandran, S. Goja, A. Soin. Sector - 38 Gurgaon, Haryana, India.
P-340
Endoscopic Balloon Dilation with Stents Placement in Biliary Stricture after Partial Liver Transplantation (PLT) – Preliminary Data. (Abstract # P-340) Yi-chun Chiu, Yu-Hung Lin, Chao-Long Chen. Kaohsiung, Taiwan.
P-341
Anatomic Similarity of the Hepatic Artery and the Portal Vein According to the Donor-Recipient Relationship. (Abstract # P-341) Tae-Seok Kim, Choon Hyuck D. Kwon, Sanghoon Lee, Hyung Hwan Moon, Sanghyun Song, Youngnam Roh, Milljae Shin, Jong Man Kim, Sung-Joo Kim, Jae-Won Joh, Suk-Koo Lee. Seoul, Korea.
P-327
P-328
P-329
Immunosuppressive Therapy with Everolimus in Liver Allograft Recipients. (Abstract # P-327) Cristina Alegre, Edurne Álvaro, Alejandro Manrique, Félix Cambra, María G. Nebreda, Rebeca Sanabria, Manuel Abradelo, Jorge Calvo, Álvaro G. Sesma, Oscar Caso, Sergio Olivares, Enrique Moreno, Carlos Jiménez. Madrid, Spain. Preliminary Short-Term Experience of Early Steroid Withdrawal after Liver Transplantation. (Abstract # P-328) Jin Wan Park, Ji Hoon Kim, Sae Byeol Choi, Jong Eun Yeon, Hyung Joon Han, Cheol Woong Jung, Wan Bae Kim, Sang Yong Choi, Kwan Soo Byun, Hyo Sun Lee. Seoul, Korea. Pulmonar Toxicity Associated to Sirolimus in Liver Transplanted Patients: Our Experience. (Abstract # P-329) Naim Fakih, Iago Justo, Oscar Caso, Maria Garcia, Edurne Alvaro, Cristina Alegre, Rebeca Sanabria, Sergio Olivares, Jorge Calvo, Alejandro Manrique, Manuel Abradelo, Felix Cambra, Alvaro Garcia, Enrique Moreno, Carlos Jimenez. Madrid, Spain.
Living Donor P-330 †
P-331 †
P-332
Impact of Pre and Post-Transplantation Portal Pressures on Outcome after Right Lobe Living Donor Liver Transplantation. (Abstract # P-330) S. K. Ramachandra, V. Satyananda, R. Mohanka, R. Kakhodkar, S. Goja, A. Rastogi, B. Menon, N. Saraf, S. Saigal, V. Vohara, S. Baijal, A. S. Soin. Gurgaon, Haryana, India. Post-Operative Pain and Its Inflencing Factors among Living Liver Donors. (Abstract # P-331) Soon Hang Lee, Kyung-Choon Lim, Mi-Kyeong Jeon, In Ok Kim, Jae Sim Jeong, Jung Ja Hong, Hea Seon Ha. Seoul, Republic of Korea. Remnant Left Liver Size and Recovery of Living Right Liver Donors. (Abstract # P-332) Yuen K. Fong, See C. Chan, Kenneth S. Chok, Albert C. Chan, William Sharr, Chung M Lo. Hong Kong, Hong Kong.
S70
Post-Transplant Lymphoproliferative Disorder in Paediatric Living Donor Liver Transplantation. (Abstract # P-342) Tian Yu Xing, Li Wei Chiang, Chao-Long Chen, Allan M. Concejero, Chih-Chi Wang, Shih-Ho Wang, Yueh-Wei Liu, Chih-Che Lin, Chee-Chien Yong. Kaohsiung, Taiwan.
P-350
Living Donor Liver Transplantation for Small (2 years after living donor LT, >1 year rejection free and normal liver function). However, an introduction of protocol biopsy for operationally tolerant patients revealed the existence of fibrosis without liver dysfunction in half of those patients. Therefore, current issue is to establish adequate IS in long-term management. Patients and Results: From June 1990 to December 2010, 719 patients under 18 years-old excluding re-transplant underwent living donor LT at Kyoto University Hospital. The 10 and 15 year patient survival rate was 81% and 78%, respectively. Of whom 204 patients were reducing or weaning cases including non-protocol weaning (49 patients) for the reason such as viral infection, side effect and non-compliance. Eighty-one patients were complete withdrawal, 48 patients were under the process of weaning, 42 patients had progressive fibrosis and 33 patients had rejection during the weaning. We re-introduced minimal maintenance IS (0.01 to 0.04 mg/kg/day of tacrolimus) for those 42 patients with progressive fibrosis. It improved fibrosis or showed no progression in 23 patients (55%), progressed fibrosis in 9 patients (21%), and 10 patients (24%) were under follow-up. Two independent factors were
S82 82
PLENARY SESSION I
complication rate in the first 15 cases was 46.7%, 20.0% in the next 15 cases, and 5.4% in the last 55 cases. The overall complication rate in the last 72 cases (4.2%) was significantly lower than the first 85 cases (15.3%) (p 1.6 on day 7, and ALT or AST > 2000 IU/L within the first 7 days post LT. Study group consisted of 21 patients who received their grafts from donors treated with sevoflurane > 1,0 vol% during procurement. Control group comprised 18 patients who received their grafts from donors without sevoflurane preconditioning. Donor risk index (DRI), MELD, AST, ALT and incidence of EAD were evaluated in both groups. Results: The groups were not different in median DRI (1,17 vs 1,23; p=0,33), MELD score (18 vs 17; p=0,69) and graft steatosis (22% vs 17%; p=0,4). Peak AST and ALT levels were lower in study group vs control, 1053 vs 2608 (p=0,18) and 721 vs 1462 (p=0,14) respectively. There was lower incidence of EAD in study group, 5 out of 21, than in control group, 11 out of 18 (Fisher test, p=0,03). In study group EAD occured in 1 of 5 recipients of grafts with moderate macrovesicular steatosis (≥30%) and in control group all 4 recipients of grafts with moderate steatosis had EAD (Fisher test, p=0,04).
Abstract# O-9 Early and Long-Term Results of Routine Microsurgical Biliary Reconstruction Technique in Living Donor Liver Transplantation. Chao-Long Chen, Tsan-Shiun Lin, Allan M. Concejero, Yuan-Cheng Chiang, Chih-Chi Wang, Shih-Ho Wang, Yueh-Wei Liu, Chee-Chien Yong. Liver Transplant Program, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Effect of sevoflurane preconditioning on incidence of EAD Study group Control group Incidence of EAD 5 of 21 (24%) 11 of 18 (61%) Incidence of EAD in recipients of 1 of 5 (20%) 4 of 4 (100%) grafts with moderate steatosis
Fisher test, p 0.025 0.048
Conclusion: This study showed statistically significant benefit of sevoflurane preconditioning for incidence of EAD in recipients of steatotic grafts, especially in case of moderate steatosis.
Objective: Our aim is to describe the long-term outcome with routine biliary reconstruction using microsurgical technique in living donor liver transplantation (LDLT). Methods: From March 22, 2006-October 30, 2008, 160 grafts were primarily transplanted in 157 LDLT recipients (including 3 dual graft transplants). All biliary reconstructions were done under microsurgical techniques by a single microsurgeon. The types of biliary reconstruction were divided to 2 groups: duct-to-duct and Roux-en-Y. The identification of early complications included up to the first year posttransplant. The minimum follow-up period to consider late biliary complications to occur was 3 years posttransplant. Nine recipients died before completing 1 year and 3 other recipients died before 3 years and were excluded from the analysis of early and late complications, respectively. Seventy-three recipients had a minimum follow-up of 3 years and 33 recipients had a minimum follow-up of 5 years. Results: There were 113 right lobe, 41 left lobe, and 3 dual grafts. The average graft duct size was 3.2 mm. There were 132 duct-to-duct reconstructions which included simple duct-to-duct (95), 2-in-1 (12), 2-to-2 (21), 2-to-1 (1), 3-in-1(1), and 3-to-3 (2). There were 33 Roux-en-Y reconstructions which included simple Roux-en-Y (28), simple duct-to-duct and Roux-en-Y (1), 2-in-1 duct-to-duct and Roux-en-Y (1), 2-in-1 Roux-en-Y (2), and 2-to-2 Roux-en-Y (1). All complications occurred in the duct-to-duct group. There was no relationship between occurrence of biliary complications and number of duct openings or liver lobe used (p>0.05). Most complications occurred during the first 15 cases and considered as the learning curve phase. The
RISING STAR SESSION Abstract# O-11 Developments in the Pediatric Liver Transplantation Since the New Allocation Rules in Eurotransplant. Uta Herden, Rainer Ganschow, Enke Grabhorn, Andrea Briem-Richter, Bjoern Nashan, Lutz Fischer. University Medical Center, Hamburg, Germany Purpose In Eurotransplant countries the allocation system for LTX was changed from a waiting time to an urgency based system using the MELD-scoring. In contrast to adults ranked by their calculated lab MELD, pediatric recipients are automatically assigned an initial pediatric MELD upgraded each 90 days until LTX. A number of analyses examine recent developments following adult LTX since the new allocation rules; however, almost no data are available concerning consequences for the pediatric population. Methods Retrospective analysis of all primary pediatric LTX from deceased donors at our center (2000-2010), divided into a time period before (until Dec 15, 2006) and after the new allocation rules.
S83 83
Abstracts
no rejection within 1 month of transplant and high mean value of tacrolimus trough concentration for 1 week of transplant in tolerance group, compared to fibrosis group (p 5mm (13.6 ± 9.3%). Conclusion Extent of hypo-perfusion likely to result from aHV privation, collateral or compensatory drainage by multiple aHV in RL LDLT can be demonstrated by NIRS-ICG. This information has potential to set new paradigms for reconstruction of aHV in LDLT.
S90 90
LIVING DONOR
Abstracts
This fact is relevant from the clinical point of view, since the use of this valuable information may avoid excessive hyperperfusion and endothelial cell injury at the time of graft reperfusion, by using any of the available procedures for graft inflow modulation (splenic artery ligation, splenectomy or partial portacaval shunt).
Abstract# O-34 Increasing the Recipient-Benefit to Donor-Risk Ratio by Lowering the Graft Size Requirement for Living Donor Liver Transplantation. See C. Chan, Kenneth S. Chok, William Sharr, Albert C. Chan, Wing C. Dai, Sheung T. Fan, Chung M. Lo. Department of Surgery, Queen Mary Hospital, Hong Kong, Hong Kong Introduction In living donor liver transplantation (LDLT), the right-liver graft is larger than the left-liver graft and hence brings better recipient survival. However, donor right hepatectomy carries a higher donor risk than donor left hepatectomy. We estimated the expansion of the applicability of left-liver LDLT (LLDLT) by lowering the graft-weight-to-standard-liver-volume ratio (GW/SLV) by every 5%. Patients and Methods Consecutive LDLTs were included in the study. Graft size prediction was made from the volume of the right or left liver by computed tomography volumetry. Estimated graft weight was derived from the volume of the leftliver graft with the conversion factor 1.19 mL/g. The proportion of LDLTs feasible by using the left liver was estimated according to the lowest GW/ SLV of 40%, 35%, 30%, and 25%. Results Totally 361 consecutive donor-recipient pairs underwent LDLT. Right-liver LDLT (RLDLT) accounted for 95% of the LDLTs. Most recipients were male (74.2%) and most donors were female (60.4%). The median GW/SLV was 46% (RLDLT, 47%; LLDLT, 37%; p=18 years). 71 (34%) were diagnosed with acute type, 126(59%) with subacute type, and 15(7%) with LOHF. Hepatitis B virus was the most common cause of acute type ALF (61.9%) whereas autoimmune hepatitis (13.4%) and drug-induced hepatitis (12.6%) were more frequent in cases with sub-acute type ALF. 209 (98%) patients underwent living donor LT. The cumulative patient survival was 80%, 73%, and 72% in 1, 5, and 10 years after LT. There were no significant difference among subgroups of ALF, with 5-year patient survival of 73% for acute type, 73% for subacute type, and 86% for LOHF (p=0.485). Preoperative patients and donor factors, including age, sex, subgroups of ALF, graft type, blood type compatibility, and etiologies were analyzed for the association with outcome after LT. Cox regression analysis failed to find pre-operative patients and donor factors associated with survival after LT. Conclusions: Long-term outcome of living donor LT for ALF was excellent regardless of etiologies and classification. LT should be considered as a treatment option in patients with ALF.
In 147 (85%) of the 173 cases with a female donor and a male recipient, the GW/SLV did not reach 30%.
S91 91
OUTCOMES
OUTCOMES
risk of liver rejection post-transplant (Figure 1; P200) but not with FDG avidity on PET. Among patients in whom preoperative imaging data was available, 69/128 patients were within Milan and 80/128 within UCSF criteria. Among those who recurred, 14 were beyond Milan and 13 beyond UCSF, patients within criteria who recurred were actually beyond UCSF on histology. The comparative 3 yr OS and RFS for patients within and outside Milan were 94% and 84% (p = 0.20) and 94% and 60% (p=0.001), respectively. Within and beyond UCSF, comparative OS and RFS at 3 years were 92% and 81% (p=0.12) and 93% and 52% (p=0.0002), respectively. Conclusion: Although UCSF criteria predict long-term survival for HCC-cirr well, LDLT may still be the best curative strategy for patients beyond them, given acceptable long term OS and RFS of 81% and 52%. While UCSF criteria should remain the determinant of suitability for DDLT, LDLT may be offered to beyond criteria patients after adequate counseling about higher recurrence and inferior survival compared to those within.
Abstract# O-38 MicroRNA Profiles in Graft Preservation Solution Predict Biliary Complications after Liver Transplantation. C. J. Verhoeven, W. R.R. Farid, P. E. de Ruiter, J. de Jonge, J. Kwekkeboom, H. J. Metselaar, H. W. Tilanus, G. Kazemier, L. J.W. van der Laan. Departments of Surgery and Gastroenterology & Hepatology, Erasmus MC, Rotterdam, Netherlands
Background and Aims Biliary complications after liver transplantation (LT) are common. Recently, hepatocyte and cholangiocyte abundant microRNAs (miRNAs) have been identified as sensitive markers for liver injury in serum. The release of miRNAs during liver injury has lead to the hypothesis that they could act as potential non-invasive biomarkers in preservation solutions to predict biliary complications after LT. The aim of this study is to investigate whether differences in the balance of hepatocyte- and cholangiocyte-derived miRNAs in graft preservation solution are predictive of biliary complications after LT. Methods Perfusate flushes from 34 consecutive grafts were collected at the end of cold ischemia time (CIT) and the cell-free solutions were analyzed for the presence of hepatocyte-abundant miRNAs (miR-122 and miR-148a) and cholangiocyte-abundant miRNAs (miR-30e miR-222 and miR-296) by quantitative RT-PCR. Mann-Whitney U tests and ROC-analyses were performed to compare ratios of miRNAs between recipients that developed biliary complications (n=11) versus recipients that did not (n=23). Results Perfusates from grafts that developed post-LT biliary complications contained significantly higher ratios of hepatocyte- (miR-122, miR-148a) and cholangiocyte- (miR-296, miR-30e, miR-222) specific miRNAs (P
